Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Overview of attention for article published in BMC Women's Health, June 2021

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 45 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 24,461 followers.

GnRH antagonists - novel modulators of estrogen to improve outcomes in endometriosis and uterine fibroids https://t.co/5ZeyNHOy3I

08 Feb 2023

Reply Repost Favourite

Safety of Relugolix treatment for women with #endometriosis-associated pain: A phase 2, randomised multi-centre study conducted by Japanese authors @UTokyo_News_en shows promising results for new treatment options, now published in #BMCWomensHealth https:/

25 Jun 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.